Trial
NCT04040725
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Dana-Farber Cancer Institute
Collaborators
Bayer
Condition
Bladder Cancer
Intervention
Rogaratinib
Why stopped
Withdrawn per Bayer
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-17